Site Members can sign up for company wide alerts
Investigation Overview
An investigation on behalf of investors, who currently hold shares of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC), was announced concerning whether the takeover of Cascadian Therapeutics Inc by Seattle Genetics, Inc for $10.00 per share is unfair to NASDAQ:CASC stockholders. The investigation by a law firm concerns whether certain officers and directors of Cascadian Therapeutics In...
You must register (for free) or login to view the entire investigation.